Prehospital statin therapy and one-year mortality in patients with stable coronary artery disease undergoing percutaneous coronary intervention

European Journal of Internal Medicine

Volumn 24, Issue 2, 2013, Pages 145-150

  Ndrepepa, Gjin ^a   King, Lamin ^a   Cassese, Salvatore ^a   Fusaro, Massimiliano ^a   Tada, Tomohisa ^a   Schömig, Albert ^a,b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coronary artery disease; Mortality; Percutaneous coronary intervention; Stable angina; Statins

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; EMERGENCY CARE; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; STABLE ANGINA PECTORIS; TREATMENT OUTCOME;

AGED; ANGINA, STABLE; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; FOLLOW-UP STUDIES; GERMANY; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84873702106     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.10.008     Document Type: Article

References (30)

1. J. Herrmann, A. Lerman, D. Baumgart, L. Volbracht, R. Schulz, and C. von Birgelen Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction Circulation 106 2002 2180 2183
2. A.W. Chan, D.L. Bhatt, D.P. Chew, M.J. Quinn, D.J. Moliterno, and E.J. Topol Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention Circulation 105 2002 691 696
3. V.L. Roger, A.S. Go, D.M. Lloyd-Jones, E.J. Benjamin, J.D. Berry, and W.B. Borden Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
4. S. Windecker, P.W. Serruys, S. Wandel, P. Buszman, S. Trznadel, and A. Linke Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
5. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, and G. Di Sciascio Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 110 2004 674 678
6. G. Di Sciascio, G. Patti, V. Pasceri, A. Gaspardone, G. Colonna, and A. Montinaro Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial J Am Coll Cardiol 54 2009 558 565
7. C. Briguori, A. Colombo, F. Airoldi, A. Violante, A. Focaccio, and P. Balestrieri Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction Eur Heart J 25 2004 1822 1828
8. C. Briguori, G. Visconti, A. Focaccio, B. Golia, A. Chieffo, and A. Castelli Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction J Am Coll Cardiol 54 2009 2157 2163
9. M. Kinoshita, S. Matsumura, K. Sueyoshi, S. Ogawa, and K. Fukuda Randomized trial of statin administration for myocardial injury: is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention? Circ J 71 2007 1225 1228
10. S. Cay, G. Cagirci, N. Sen, Y. Balbay, T. Durmaz, and S. Aydogdu Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin Cardiovasc Drugs Ther 24 2010 41 47
11. J. Veselka, D. Zemanek, P. Hajek, M. Maly, R. Adlova, and L. Martinkovicova Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study Am J Cardiol 104 2009 630 633
12. H. Bozbas, A. Yildirir, S. Mermer, D. Konas, I. Atar, and A. Aydinalp Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention? Adv Ther 24 2007 493 504
13. G. Patti, C.P. Cannon, S.A. Murphy, S. Mega, V. Pasceri, and C. Briguori Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies Circulation 123 2011 1622 1632
14. G. Ndrepepa, T. Tada, M. Fusaro, S. Cassese, L. King, and M. Hadamitzky Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease Clin Res Cardiol 101 2012 1003 1011
15. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
16. G.G. Gensini A more meaningful scoring system for determining the severity of coronary heart disease Am J Cardiol 51 1983 606
17. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, and G.A. van Es Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
18. U. Dafni Landmark analysis at the 25-year landmark point Circ Cardiovasc Qual Outcomes 4 2011 363 371
19. I. Jialal, D. Stein, D. Balis, S.M. Grundy, B. Adams-Huet, and S. Devaraj Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels Circulation 103 2001 1933 1935
20. J. Dupuis, J.C. Tardif, P. Cernacek, and P. Theroux Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial Circulation 99 1999 3227 3233
21. G. Patti, M. Chello, V. Pasceri, D. Colonna, A. Nusca, and M. Miglionico Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy J Am Coll Cardiol 48 2006 1560 1566
22. S. Matetzky, P. Fefer, B. Shenkman, M. Shechter, I. Novikov, and N. Savion Statins have an early antiplatelet effect in patients with acute myocardial infarction Platelets 22 2011 103 110
23. K. Fujii, D. Kawasaki, K. Oka, H. Akahori, T. Iwasaku, and M. Fukunaga The impact of pravastatin pre-treatment on periprocedural microcirculatory damage in patients undergoing percutaneous coronary intervention JACC Cardiovasc Interv 4 2011 513 520
24. S.R. Mulukutla, O.C. Marroquin, C. Smith, R. Varghese, W.D. Anderson, and J.S. Lee Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury Am J Cardiol 94 2004 1363 1366
25. C. Auguadro, M. Manfredi, F. Scalise, A. Mortara, and G. Specchia Protective role of chronic statin therapy in reducing myocardial damage during percutaneous coronary intervention J Cardiovasc Med (Hagerstown) 7 2006 416 421
26. J. Gordin, A. Haider, R.V. Swaminathan, L.K. Kim, R.M. Minutello, and G. Bergman Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention Am J Cardiol 110 2012 1397 1404
27. Y. Ye, J.R. Perez-Polo, and Y. Birnbaum Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions Ann N Y Acad Sci 1207 2010 76 82
28. J.L. Zhao, Y.J. Yang, C.J. Cui, S.J. You, and R.L. Gao Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel Br J Pharmacol 149 2006 243 249
29. R.M. Bell, and D.M. Yellon Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway J Am Coll Cardiol 41 2003 508 515
30. X.L. Tang, S.K. Sanganalmath, H. Sato, Q. Bi, G. Hunt, and R.J. Vincent Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction PLoS One 6 2011 e25320